9582
I. Rodríguez et al. / Tetrahedron 68 (2012) 9578e9582
116.81, 120.00, 123.18, 128.30, 137.87, 152.41, 159.66. HRMS (ESI)
References and notes
C12H16F3NNaO7S [MþNa]þ: calcd 398.0492, found 398.0494.
1. Peptide and Protein Design for Biopharmaceutical Applications; Jensen, K. J., Ed.;
John Wiley & Sons: Chichester, UK, 2009.
2. Panday, S. K. Tetrahedron: Asymmetry 2011, 22, 1817e1847.
4.4. Synthesis of methyl N-(tert-butoxycarbonyl)-3-phenyl-
D
ꢀ
3. (a) Sayago, F. J.; Laborda, P.; Calaza, M. I.; Jimenez, A. I.; Cativiela, C. Eur. J. Org.
2-pyrroline-2-carboxylate, 3
ꢀ~
Chem. 2011, 2011e2028; (b) Cativiela, C.; Ordonez, M. Tetrahedron: Asymmetry
2009, 20, 1e63; (c) Calaza, M. I.; Cativiela, C. Eur. J. Org. Chem. 2008,
3427e3448; (d) Karoyan, P.; Sagan, S.; Lequin, O.; Quancard, J.; Lavielle, S.;
Chassaing, G. Substituted Prolines: Syntheses and Applications in Structure-
Activity Relationship Studies of Biologically Active Peptides. In Targets in Het-
erocyclic Systems. Chemistry and Properties; Attanasi, O. A., Spinelli, D., Eds.;
Royal Society of Chemistry: Cambridge, 2005; Vol. 8, pp 216e273; (e) Cativiela,
C.; Díaz-de-Villegas, M. D. Tetrahedron: Asymmetry 2000, 11, 645e732.
4. (a) MacArthur, M. W.; Thornton, J. M. J. Mol. Biol. 1991, 218, 397e412; (b) Rose,
G. D.; Gierasch, L. M.; Smith, J. A. Adv. Protein Chem. 1985, 37, 1e109; (c)
Chakrabarti, P.; Pal, D. Prog. Biophys. Mol. Biol. 2001, 76, 1e102.
To a solution of 4 (7.20 g, 19.18 mmol) and phenylboronic acid
(4.68 g, 38.36 mmol) in a 10:1 mixture of toluene/methanol
(154 mL), potassium carbonate (4.00 g, 28.94 mmol) and [1,1-
bis(diphenylphosphino)ferrocene] dichloropalladium (II) (700 mg,
0.96 mmol) were added. The reaction mixture was stirred at
80e85 ꢀC for 18 h. The solvent was concentrated in vacuo and the
resulting residue was purified by silica gel column chromatography
(eluent: hexanes/ethyl acetate 4:1) to afford pure 3 as a white solid
5. Mauger, A. B. J. Nat. Prod. 1996, 59, 1205e1211.
ꢀ
ꢀ
6. Fatas, P.; Jimenez, A. I.; Calaza, M. I.; Cativiela, C. Org. Biomol. Chem. 2012, 10,
640e651.
(5.60 g, 18.46 mmol, 96% yield). Mp 66 ꢀC. IR (neat)
1701, 1627 cmꢁ1. 1H NMR (CDCl3, 400 MHz)
1.49 (s, 9H), 3.04 (m,
2H), 3.83 (s, 3H), 3.97 (m, 2H), 7.22e7.38 (m, 5H). 13C NMR (CDCl3,
n 2978, 1739,
7. (a) Maillard, M. C.; Brookfield, F. A.; Courtney, S. M.; Eustache, F. M.; Gemkow,
M. J.; Handel, R. K.; Johnson, L. C.; Johnson, P. D.; Kerry, M. A.; Krieger, F.;
d
~
ꢀ
Meniconi, M.; Munoz-Sanjuan, I.; Palfrey, J. J.; Park, H.; Schaertl, S.; Taylor, M.
G.; Weddell, D.; Dominguez, C. Bioorg. Med. Chem. 2011, 19, 5833e5851; (b)
Falcioni, F.; Ito, K.; Vidovic, D.; Belunis, C.; Campbell, R.; Berthel, S. J.; Bolin, D.
R.; Gillespie, P. B.; Huby, N.; Olson, G. L.; Sarabu, R.; Guenot, J.; Madison, V.;
Hammer, J.; Sinigaglia, F.; Steinmetz, M.; Nagy, Z. A. Nat. Biotechnol. 1999, 17,
562e567; (c) Bolin, D. R.; Swain, A. L.; Sarabu, R.; Berthel, S. J.; Gillespie, P.;
Huby, N. J. S.; Makofske, R.; Orzechowski, L.; Perrotta, A.; Toth, K.; Cooper, J. P.;
Jiang, N.; Falcioni, F.; Campbell, R.; Cox, D.; Gaizband, D.; Belunis, C. J.; Vidovic,
D.; Ito, K.; Crowther, R.; Kammlott, U.; Zhang, X.; Palermo, R.; Weber, D.;
Guenot, J.; Nagy, Z.; Olson, G. L. J. Med. Chem. 2000, 43, 2135e2148; (d) Ro-
sloniec, E. F.; Brandstetter, T.; Leyer, S.; Schwaiger, F.-W.; Nagy, Z. A. J. Auto-
immun. 2006, 27, 182e195; (e) Cai, M.; Cai, C.; Mayorov, A. V.; Xiong, C.; Cabello,
C. M.; Soloshonok, V. A.; Swift, J. R.; Trivedi, D.; Hruby, V. J. J. Pept. Res. 2004, 63,
116e131; (f) McFadyen, I. J.; Sobczyk-Kojiro, K.; Schaefer, M. J.; Ho, J. C.; Omnaas,
J. R.; Mosberg, H. I.; Traynor, J. R. J. Pharmacol. Exp. Ther. 2000, 295, 960e966; (g)
Tong, Y.; Fobian, Y. M.; Wu, M.; Boyd, N. D.; Moeller, K. D. J. Org. Chem. 2000, 65,
2484e2493; (h) Tong, Y.; Fobian, Y. M.; Wu, M.; Boyd, N. D.; Moeller, K. D. Bi-
oorg. Med. Chem. Lett. 1998, 8, 1679e1682; (i) Armishaw, C.; Jensen, A. A.; Balle,
T.; Clark, R. J.; Harpsøe, K.; Skonberg, C.; Liljefors, T.; Strømgaard, K. J. Biol. Chem.
2009, 284, 9498e9512.
100 MHz)
d 28.38, 32.25, 46.68, 52.53, 81.55, 126.47, 127.66, 128.51,
129.74, 133.88, 151.93, 164.49. HRMS (ESI) C17H21NNaO4 [MþNa]þ:
calcd 326.1363, found 326.1358.
4.5. Synthesis of methyl cis-N-(tert-butoxycarbonyl)-3-
phenylpyrrolidine-2-carboxylate, cis-1
A mixture of 3 (5.60 g, 18.46 mmol) and 10% Pd/C (600 mg) in
methanol (56 mL) was stirred overnight at room temperature un-
der an atmospheric pressure of hydrogen gas. The catalyst was
filtered off and washed with methanol. The solvent was concen-
trated in vacuo to afford pure cis-1 as a white solid (5.60 g,
18.34 mmol, 99% yield). Spectroscopic data were coincident with
those reported.9
8. (a) Kamenecka, T. M.; Park, Y.-J.; Lin, L. S.; Lanza, T., Jr.; Hagmann, W. K. Tet-
rahedron Lett. 2001, 42, 8571e8573; (b) Herdeis, C.; Hubmann, H. P.; Lotter, H.
Tetrahedron: Asymmetry 1994, 5, 351e354; (c) Oba, M.; Saegusa, T.; Nishiyama,
N.; Nishiyama, K. Tetrahedron 2009, 65, 128e133; (d) Flamant-Robin, C.; Wang,
Q.; Chiaroni, A.; Sasaki, N. A. Tetrahedron 2002, 58, 10475e10484; (e) Solo-
shonok, V. A.; Ueki, H.; Tiwari, R.; Cai, C.; Hruby, V. J. J. Org. Chem. 2004, 69,
4984e4990; (f) Micheli, F.; Di Fabio, R.; Marchioro, C. Il Farmaco 1999, 54,
4.6. Synthesis of methyl trans-N-(tert-butoxycarbonyl)-3-
phenylpyrrolidine-2-carboxylate, trans-1
€
A 1 M solution of LiHMDS in tetrahydrofuran (14.73 mL,
14.73 mmol) was added dropwise to a solution of cis-1 (3.00 g,
9.82 mmol) in tetrahydrofuran (80 mL) and the resulting mixture
was stirred for 2 h at room temperature. After quenching with
water, the mixture was extracted with diethyl ether (3ꢂ50 mL) and
washed with brine (50 mL). The organic layer was dried over
MgSO4, filtered and evaporated under reduced pressure. The crude
5:95 mixture of cis/trans isomers was submitted to column chro-
matography (eluent: hexanes/ethyl acetate 3:1) to afford pure
trans-1 (1.90 g, 6.22 mmol, 63% yield); further chromatographic
purification of the remaining diastereomeric mixture to increase
the isolated yield of trans-1 was not carried out. Spectroscopic data
were coincident with those reported.9
461e464; (g) Schollkopf, U.; Pettig, D.; Busse, U.; Egert, E.; Dyrbusch, M. Syn-
thesis 1986, 737e740; (h) Delaye, P.-O.; Vasse, J.-L.; Szymoniak, J. Org. Biomol.
Chem. 2010, 8, 3635e3637; (i) Evans, M. C.; Johnson, R. L. Tetrahedron 2000, 56,
€
9801e9808; (j) Laabs, S.; Munch, W.; Bats, J. W.; Nubbemeyer, U. Tetrahedron
2002, 58, 1317e1334; (k) Gotoh, H.; Okamura, D.; Ishikawa, H.; Hayashi, Y. Org.
ꢀ
Lett. 2009, 11, 4056e4059; (l) Rios, R.; Ibrahem, I.; Vesely, J.; Sunden, H.;
ꢀ
Cordova, A. Tetrahedron Lett. 2007, 48, 8695e8699.
ꢀ
ꢀ
9. Fatas, P.; Gil, A. M.; Calaza, M. I.; Jimenez, A. I.; Cativiela, C. Chirality, http://dx.
10. Chung, J. Y. L.; Wasicak, J. T.; Arnold, W. A.; May, C. S.; Nadzan, A. M.; Holladay,
M. W. J. Org. Chem. 1990, 55, 270e275.
11. For a recent review on the access and applications of vinyl triflates derived from
1,3-dicarbonyl compounds, see: Chassaing, S.; Specklin, S.; Weibel, J.-M.; Pale, P.
Tetrahedron 2012, 68, 7245e7273.
12. (a) Pellegrini, N.; Schmitt, M.; Bourguignon, J.-J. Tetrahedron Lett. 2003, 44,
6779e6780; (b) Tran, J. A.; Tucci, F. C.; Arellano, M.; Jiang, W.; Chen, C. W.;
Marinkovic, D.; Fleck, B. A.; Wen, J.; Foster, A. C.; Chen, C. Bioorg. Med. Chem.
Lett. 2008, 18, 1931e1938.
13. Blake, J.; Willson, C. D.; Rapoport, H. J. Org. Chem. 1964, 86, 5293e5299.
14. (a) Moreau, R. J.; Sorensen, E. J. Tetrahedron 2007, 63, 6446e6453; (b) Moyer,
M. P.; Feldman, P. L.; Rapoport, H. J. Org. Chem. 1985, 50, 5223e5230.
15. Brooks, D. W.; Lu, L. D.-D.; Masamune, S. Angew. Chem., Int. Ed. Engl. 1979, 18,
72e74.
Acknowledgements
The authors thank the Ministerio de Ciencia
cioneFEDER (grant CTQ2010-17436; FPI fellowship to I.R.) and
e Innova-
16. A detailed experimental procedure is not given.
ꢀ
17. (a) Comins, D. L.; Dehghani, A. Tetrahedron Lett. 1992, 33, 6299e6302; (b)
Comins, D. L.; Dehghani, A.; Foti, C. J.; Joseph, S. P. Org. Synth. 1997, 74, 77e83.
18. Vinyl triflate 4 also proved stable when stored overnight at ꢁ20 ꢀC.
ꢀ
Gobierno de AragoneFSE (research group E40) for financial
support.